IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1101-1125 out of 1239.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

Public Release: 20-Mar-2014
American Journal of Human Genetics
New tool pinpoints genetic sources of disease
Many diseases have their origins in either the genome or in reversible chemical changes to DNA known as the epigenome. Now, results of a new study from Johns Hopkins scientists show a connection between these two 'maps.' The findings, reported March 20 in the American Journal of Human Genetics, could help disease trackers find patterns that offer clues to the causes of and possible treatments for complex genetic conditions, including many cancers and metabolic disorders.
NIH/National Human Genome Research Institute, NIH/National Institute on Aging, Swedish AFA Insurance, Swedish Foundation for Strategic Research, European Research Council

Contact: Shawna Williams
Johns Hopkins Medicine

Public Release: 20-Mar-2014
Institut Pasteur and Myriad RBM publish results from landmark study of immune response
Institut Pasteur and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy human immune response. The Milieu Interieur project will characterize the immune phenotypes of 1,000 healthy subjects. The results could lead to the development of novel diagnostics and companion diagnostics.

Contact: Ron Rogres
Myriad Genetics, Inc.

Public Release: 20-Mar-2014
Cells do not repair damage to DNA during mitosis because telomeres could fuse together
Throughout a cell's life, corrective mechanisms act to repair DNA strand breaks. The exception is during the critical moment of cell division, when chromosomes are most vulnerable. Toronto researchers found out why DNA repair shuts down during mitosis.
Canadian Institutes of Health Research, others

Contact: Polly Thompson
Lunenfeld-Tanenbaum Research Institute

Public Release: 20-Mar-2014
New approach makes cancer cells explode
Researchers at Karolinska Institutet in Sweden have discovered that a substance called Vacquinol-1 makes cells from glioblastoma, the most aggressive type of brain tumor, literally explode. The findings are published in the journal Cell.
Swedish Cancer Society, Swedish Foundation for Strategic Research, others

Contact: Press Office
Karolinska Institutet

Public Release: 20-Mar-2014
Cell Stem Cell
Proteins that control energy use necessary to form stem cells
Two proteins that control how cells metabolize glucose play a key role in the formation of human stem cells. Studies suggest these proteins which also play a role in the process that transforms normal cells into cancer stem cells, might also be targets for new cancer therapies.
American Heart Association, Tietze Award, National Institutes of Health

Contact: Kim Blakeley
University of Washington Health Sciences/UW Medicine

Public Release: 20-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Regular physical activity reduces breast cancer risk irrespective of age
Practicing sport for more than an hour day reduces the risk of contracting breast cancer, and this applies to women of any age and any weight, and also unaffected by geographical location, according to research presented to the 9th European Breast Cancer Conference. Compared with the least active women, those with the highest level of physical activity reduced their risk of breast cancer by 12 percent, researchers say.

Contact: Mary Rice
ECCO-the European CanCer Organisation

Public Release: 20-Mar-2014
Developmental Cell
New type of cell communication regulates blood vessel formation and tumor growth
When tumours grow, new blood vessels are formed that deliver oxygen and nutrients to the tumour cells. A research group at Uppsala University has discovered a new type of cell communication that results in suppressed blood vessel formation and delayed tumor growth. The results might explain why healthy individuals can have microscopic tumors for many years, which do not progress without formation of new blood vessels.

Contact: Lena Claesson-Welsh
Uppsala University

Public Release: 20-Mar-2014
Cancer Cell
Study reveals a major mechanism driving kidney cancer progression
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP -- which normally suppresses tumor growth -- to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation. This cytoplasmic accumulation of SPOP is sufficient to convey tumorigenic properties onto otherwise non-tumorigenic cells.
National Institutes of Health, Beijing Science Foundation, Keck Foundation, Chicago Community Trust, Chicago Biomedical Consortium

Contact: John Easton
University of Chicago Medical Center

Public Release: 20-Mar-2014
Colonoscopy isn't perfect: About 6 percent of colorectal cancers are missed
About 6 percent of colorectal cancers are diagnosed within three to five years after the patient receives a clean colonoscopy report, according to a population-based study by researchers from Huntsman Cancer Institute at the University of Utah.
Huntsman Cancer Institute, NIH/National Cancer Institute

Contact: Linda Aagard
University of Utah Health Sciences

Public Release: 20-Mar-2014
Molecular Cell
Gene silencing instructions acquired through 'molecular memory' tags on chromatin
Scientists at Indiana University have unlocked one of the mysteries of modern genetics: how acquired traits can be passed between generations in a process called epigenetic inheritance.

Contact: Steve Chaplin
Indiana University

Public Release: 20-Mar-2014
Journal of Clinical Investigation
Inhibition of CDK4 might promote lymphoma development and progression
Anticancer agents that inhibit tumor growth by targeting a cell-cycle regulatory protein called CDK4 might actually promote the development and progression of certain B-cell lymphomas. The research suggests that CDK4 inhibitors, which are now in clinical testing, should be used cautiously, particularly in patients with B-cell lymphomas. The findings raise the possibility that these inhibitors work through off-target effects and require further investigation.
NIH/National Cancer Institute

Contact: Darrell E. Ward
Ohio State University Wexner Medical Center

Public Release: 20-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Deaths from breast cancer fall in Europe
Improvements in treatment, as well as enhanced access to care, underlie the sustained decreases in breast cancer mortality seen in 30 European countries from 1989 to 2010. But there are notable variations between different countries that cannot be explained simply by the resources devoted to cancer care, and these differences need to be studied further.

Contact: Mary Rice
ECCO-the European CanCer Organisation

Public Release: 20-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Obesity and diabetes have adverse effects on cancer outcomes
Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive chemotherapy as primary treatment before surgery, according to research to be presented at the 9th European Breast Cancer Conference on March 21. Although a high body mass index is known to have a negative impact on cancer development and prognosis, until now there has been uncertainty as to whether having a high body mass index had an equal effect on patients with different types of breast tumors.

Contact: Mary Rice
ECCO-the European CanCer Organisation

Public Release: 19-Mar-2014
55th ASH Annual Meeting and Exposition
Chemo-free treatment a possibility for leukemia/lymphoma
Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves a patient's life expectancy and quality of life.

Contact: Andrew Gould
University of Plymouth

Public Release: 19-Mar-2014
The 9th European Breast Cancer Conference (EBCC-9)
Genetic testing may help select women with ER+ breast cancer for extended hormone therapy
Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than five. The research is presented at the European Breast Cancer Conference in Glasgow.

Contact: Emma Mason
ECCO-the European CanCer Organisation

Public Release: 19-Mar-2014
New England Journal of Medicine
New, noninvasive, stool-based colorectal cancer screening test
A new, noninvasive, stool-based screening test detected 92 percent of colorectal cancer, according to a multicenter trial published online today in the New England Journal of Medicine. The new test, which is not yet approved by the FDA, allows patients to collect a sample at home without the need for bowel preparation or diet restrictions.
Exact Sciences Corporation

Contact: Johanna Younghans
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 19-Mar-2014
New England Journal of Medicine
Noninvasive colorectal cancer screening tool shows unprecedented detection rates
Results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test. The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine. Cologuard was co-developed by Mayo Clinic and Exact Sciences.
Exact Sciences

Contact: Brian Kilen
Mayo Clinic

Public Release: 19-Mar-2014
New England Journal of Medicine
Genetic test could improve colon cancer screening
A non-invasive test that includes detection of the genetic abnormalities related to cancer could significantly improve the effectiveness of colon cancer screening, according to research published by a team of scientists including David Ransohoff, M.D., professor of medicine at the University of North Carolina School of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center member.

Contact: Katy Jones
University of North Carolina Health Care

Public Release: 19-Mar-2014
Molecular Systems Biology
101 liver cancer drug candidates pave the way to personalized medicine
The heart disease drug perhexiline is one of 101 compounds predicted to prevent cancer growth in most patients suffering from our most common liver cancer, HCC. This is an outcome from a novel simulation-based approach using personal sets of proteins of six HCC patients. 'This is the first time personalized models have been used to find and evaluate new potential drugs,' says professor Jens Nielsen at Chalmers University of Technology.
Knut and Alice Wallenberg Foundation

Contact: Christian Borg
Chalmers University of Technology

Public Release: 19-Mar-2014
New England Journal of Medicine
North Shore-LIJ Cancer Institute doctors' editorial published
Two North Shore-LIJ Cancer Institute doctors, world-renowned for their research in chronic lymphocytic leukemia (CLL), weigh in on a German study of a new drug therapy for CLL in the March 20 edition of the New England Journal of Medicine, the North Shore-LIJ Health System announced today.

Contact: Diane O'Donnell
North Shore-Long Island Jewish (LIJ) Health System

Public Release: 19-Mar-2014
Journal of Thoracic and Cardiovascular Surgery
Patients enjoy good quality of life 10 years after esophagectomy and gastric pull-up
Long-term survivors after esophagectomy with gastric pull-up can enjoy a satisfying meal and good quality of life according to a new study from a team of researchers at the University of Southern California Keck School of Medicine, Los Angeles. This study concluded that pessimism about the long-term quality of life after an esophagectomy on the part of treating physicians and patients is unwarranted. It is published in the Journal of Thoracic and Cardiovascular Surgery.

Contact: Nicole Baritot
American Association for Thoracic Surgery

Public Release: 19-Mar-2014
World Journal of Surgery
TGen study identifies gene fusion as likely cause of rare type of thyroid cancer
In a scientific first, the fusion of two genes, ALK and EML4, has been identified as the genetic driver in an aggressive type of thyroid cancer, according to a study by the Translational Genomics Research Institute. These groundbreaking findings are based on genetic sequencing of tumor cells from a 62-year-old patient with an aggressive tall cell variant of papillary thyroid cancer, according to the study published Tuesday, March 18, in the World Journal of Surgery.

Contact: Steve Yozwiak
The Translational Genomics Research Institute

Public Release: 19-Mar-2014
Journal of Clinical Investigation
Inflammation mobilizes tumor cells
Researchers of Ludwig-Maximilians-Universitaet in Munich have discovered a novel feedback mechanism that provides a mechanistic link between chronic inflammation and carcinogenesis.
German Cancer Aid Society, German Consortium for Translational Cancer Research

Contact: Luise Dirscherl
Ludwig-Maximilians-Universität München

Public Release: 19-Mar-2014
Journal of Leukocyte Biology
Researchers uncover allergy-cancer connection
While many are stocking up on allergy medicine in preparation for spring, a new study from researchers at Virginia Commonwealth University Massey Cancer Center has uncovered a new connection between allergy and cancer that could potentially lead to therapies involving common antihistamines.
National Institutes of Health, National Health & Medical Research Council, American Asthma Foundation

Contact: Alaina Schneider
Virginia Commonwealth University

Public Release: 19-Mar-2014
Journal of Clinical Oncology
Increased risk of relapse omitting RT in early PET scan negative Hodgkin's lymphoma
Interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial published in the Journal of Clinical Oncology indicates an increased risk of early relapse when omitting radiotherapy in early PET scan negative patients with stage I/II Hodgkin's lymphoma. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these initial findings are maintained over time.

Contact: John Bean
European Organisation for Research and Treatment of Cancer

Showing releases 1101-1125 out of 1239.

<< < 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 > >>

  Search News Releases